spacer
home > pmps > spring 2007 > beating the blood brain barrier
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Beating the Blood Brain Barrier

Jamal Temsamani and Claude Laruelle of CLL Pharma go in search of a method that overcomes a formidable obstacle blocking the delivery of drugs to the brain

The prevalence of neurodegenerative diseases such as Parkinsonís disease, stroke, and Alzheimerís disease is increasing as the population ages. This, together with brain cancers, viral infections such as HIV, the threat of Creutzfeldt- Jakob disease and a broad range of psychophysical conditions, are putting increasing pressure on pharmaceutical companies to produce more effective drugs for brain disorders.

Brain diseases, however, are difficult to treat, not least because the brain is a highly complex and delicate organ, but also because it is inaccessible to many therapeutic molecules due to the blood brain barrier (BBB). It is estimated that this barrier prevents about 98 per cent of systemically delivered potential neurotherapeutics from entering the brain. Many novel drugs are under development, but to exploit new therapeutic approaches to the full, there is a compelling need for drug developers to find improved ways of overcoming the BBB.

THE NATURE OF THE BBB

The existence of the BBB was first suspected in the late 1800s, when it was noticed that water-soluble dyes injected into the blood stream did not stain the brain and spinal cord. The diffusion of a variety of molecules that readily distribute in many other organs simply does not occur at the BBB. Here, endothelial cells in the walls of blood vessels in the brain form a close-fitting monolayer connected by complex and largely impassably tight junctions (see Figure 1). Each brain capillary endothelial cell, in addition, is composed of two lipid membranes: the lumenal (facing the blood) and the ablumenal (facing the brain), which are separated by approximately 300nm of endothelial cytoplasm.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Jamal Temsamani, PhD, joined CLL Pharma following the acquisition of Syntem. He has been the Vice President of Pre-Clinical Research and Development at Syntem since 1998. Jamal received his PhD in Molecular Biology from the University of Montpellier, France. After completing a post-doctoral fellowship at the Worcester Foundation for Biomedical Research, he joined Hybridon, Inc (MA, USA), where he served as Associate Director and Director of Discovery Group. In 1997, he was appointed Scientific Director of Hybridon Europe, where he was responsible for supervising and co-ordinating European collaborations. He has published more than 61 scientific articles and six book chapters and is co-inventor of 40 patents.

Claude Laruelle, PhD, is the Chief Executive Officer of CLL Pharma. Before founding CLL Pharma in 1995, he was CEO and R&D Director of Panmedica. He has held several other positions such as Vice President of pharmaceutical consulting firm Droit & Pharmacie and Research Engineer at Labaz-Sanofi. Claude holds a PhD in Physics and is a Chemical Engineer. He has developed 210 market authorisations for generics in Europe, is an inventor of 280 patents, and is the author of 27 scientific communications.

spacer
Jamal Temsamani
spacer
spacer
spacer
Claude Laruelle
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Destiny Pharma appoints MedPharm to develop new XF-platform drug formulations

Destiny Pharma, a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, is pleased to announce that it has appointed MedPharm as its expert partner to develop new topical formulations of the Companyís novel XF-platform compounds. These new treatments for dermal and ocular infections are part of its second clinical programme to address the global problem of anti-microbial resistance (AMR). MedPharm is a world leading contract provider of topical and transdermal product design and formulation development services using sophisticated in vitro models to de-risk development programmes.
More info >>

White Papers

Keeping Abreast of the Competitive Environment in Clinical Development

Thomson Reuters

Strategic management of a therapy area requires hard decisions to be made about which programs to invest in and which to let go. Understanding the rapidly changing competitive environment for your drug candidates is a key input into these decisions. It is easy to lose track of the broader picture when a clinical program is in progress and get blindsided by external events.
More info >>

 
Industry Events

Nordic Life Science Days 10/12 September 2019

10-12 September 2019, Malmo Sweden

Nordic Life Science Days is the largest Nordic partnering conference for the global Life Science industry. Bringing together the best talents in Life Science, offering amazing networking and partnering opportunities, providing inputs and content on the most recent trends. Nordic Life Science Days attracts leading decision makers from the Life Science sector, not only from biotech, pharma and medtech but also from finances, research, policy and regulatory authorities.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement